A Study to Investigate the Efficacy and Safety of Ivonescimab Combined With Irinotecan Liposome as Second-line Regimen for ES-SCLC

NCT06478043 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

54

Enrollment

OTHER

Sponsor class

Conditions

Extensive-stage Small-cell Lung Cancer

Interventions

DRUG: ivonescimab
DRUG: irinotecan liposome

Sponsor

Zhejiang Cancer Hospital